Remicade biosim floats through EU approval
This article was originally published in Scrip
The European Commission has given Hospira/Celltrion's version of J&J/Merck & Co's anti-TNF monoclonal antibody Remicade (infliximab) the formal green light after what seems to have been a very smooth approval process.
You may also be interested in...
The past decade has been transformative for the global biosimilars industry as regulators, developers, physicians, patients and payers from all over the world have grappled with complex, and often market-shaping, issues.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.